Medical Transcription Billing, Corp. (MTBC) shares saw a recent bid of $1.80 and 10.78M shares have exchanged hands in the recent trading session, yielding a 7.78% gain over the past week. The stock price increased 16.88% or $-0.26 versus $1.54 at the end of the prior session. This change led market cap to move at $21.47M, putting the price -53.13% below the 52-week high and 520.69% above the 52-week low. The company’s stock has a normal trading capacity of 1.98M shares while the relative volume is 5.45.
To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $2.25 while $2.25 target is by far the most aggressive out of analysts who are currently evaluating the company, $0 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $2.25, which would be an increase of about 25% of its current value. The mean target of $2.25 should be compared with the price when the stock was languishing around $0.29 a share. And it remains to be seen which target price MTBC can achieve without sacrificing much as the company is holding a 97.80% gain for the past twelve months.
By historical standards, Medical Transcription Billing, Corp. remains a cheap stock. The company’s current price-earnings ratio amounts above the average P/E ratio of 38.34 times earnings. For now, Medical Transcription Billing, Corp. is the toast of Wall Street as its ABR stands at 2.00 with 0 out of 1 analysts rating the stock a buy. Over the short term, some market observers may have noticed that Medical Transcription Billing, Corp. has a 8.46% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. Medical Transcription Billing, Corp. has far performed well this year, with the share price up 148.28% since January. Over the past 2 quarters, the stock is up 109.30%, compared with a gain of nearly 170.35% for 3 months and about -8.63% for the past 30 days.
Revenue for the quarter also killed consensus, coming in at $8.22M, compared to the consensus of 7.9M. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $-0.24. The company is expected to report EPS as high as $-0.24 and as low as $-0.24 per share. Similarly, full-year EPS forecasts have ranged between $-0.97 and $-0.97. The mean EPS estimate is $-0.97. On the other side, sales forecasts for the current quarter are $8.1M. The stock is expected to report revenue as high as $8.1M and as low as $8.1M per share. Similarly, full-year sales forecasts have ranged between $32.6M and $32.6M. The mean revenue estimate is $32.6M.
Over the last 5 years, Medical Transcription Billing, Corp. has a 19.40% revenue growth rate. Analysts are expecting EPS growth rates to be at -106.70% this quarter and EPS estimate for next year reflect 17.30% growth rate.
Sell-side analysts also have something to say about this company. Chardan Capital Markets analysts stated on 15/05/2017 that they maintained their Buy rating. Chardan Capital Markets analysts stated on 13/08/2015 that they maintained their Buy rating. Summer Street Research analysts stated on 03/09/2014 that they launched coverage on this stock with Buy rating.